Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice
Authors:
- Jorge BoánJBJorge Boán
- Eduardo Aparicio‐MinguijónEAEduardo Aparicio‐Minguijón
- Mario Fernández‐RuizMFMario Fernández‐Ruiz
- María Asunción Pérez‐Jacoiste AsínMAMaría Asunción Pérez‐Jacoiste Asín
- Isabel Rodríguez‐GoncerIRIsabel Rodríguez‐Goncer
- Francisco López‐MedranoFLFrancisco López‐Medrano
- Rafael San‐JuanRSRafael San‐Juan
- José Tiago SilvaJSJosé Tiago Silva
- Ana Pérez‐AyalaAPAna Pérez‐Ayala
- Jose Manuel Caro‐TellerJCJose Manuel Caro‐Teller
- José María AguadoJAJosé María Aguado
Open Access
Abstract
Background: Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings. Objectives: We aimed to describe our real‐world experience with rezafungin for the treatment of invasive fungal disease (IFD). Patients: A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted. Results: We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical intervention (38.5%). Most frequent Candida species were C. albicans (38.5%), C. parapsilosis (30.8%) and Nakaseomyces glabratus (15.4%). One patient had necrotizing gingival infection due to Trichoderma longibrachiatum. Main types of IFD included intravascular Candida infection (38.5%) and surgical‐site and intra‐abdominal candidiasis (23.1% each). Reported reasons for initiating rezafungin were the presence of fluconazole‐resistant isolates (53.8%), facilitating outpatient antifungal therapy (30.8%) and avoiding anticipated drug–drug interactions with triazoles (15.4%). No patient received rezafungin as a first‐line treatment and most (92.3%) had been previously exposed to other echinocandins. Rezafungin was typically initiated upon clearance of follow‐up blood cultures (80.0%). Median number of weekly doses was 4.0 (interquartile range: 3.0–5.5). Clinical cure (complete or partial response) by day +30 was achieved in all evaluable patients (100.0% [12/12]), with no treatment‐emergent adverse events. Conclusions: Rezafungin was effective and safe as salvage or consolidation therapy in patients with IFD, including deep‐seated candidiasis.Keywords
Funding Information
- Instituto de Salud Carlos III (CM25/00250)
- Instituto de Salud Carlos III (CM25/00243)
- Instituto de Salud Carlos III (JR24/00034)
This publication has 46 references indexed in Scilit:
- Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST methodClinical Microbiology and Infection, 2018
- Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel EchinocandinAntimicrobial Agents and Chemotherapy, 2016
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2015
- Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm DrugsMicrobiology Spectrum, 2015
- ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patientsClinical Microbiology and Infection, 2012
- Activities of Triazole-Echinocandin Combinations against Candida Species in Biofilms and as Planktonic CellsAntimicrobial Agents and Chemotherapy, 2011
- Echinocandin Antifungal Drugs in Fungal InfectionsDrugs, 2011
- Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus CriteriaClinical Infectious Diseases, 2008
- Echinocandin antifungal drugsThe Lancet, 2003
- Antifungal Susceptibility ofCandidaBiofilms: Unique Efficacy of Amphotericin B Lipid Formulations and EchinocandinsAntimicrobial Agents and Chemotherapy, 2002